SCHEMBL3198121

SCHEMBL3198121

COC(=O)C#CC(=O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.52
KMT2A Q03164 3/20 0.45
CES1 P23141 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
MEN1 O00255 2/20 0.45
MAPT P10636 2/20 0.45
HPGD P15428 2/20 0.45
KDM4E B2RXH2 1/20 0.45
CYP3A4 P08684 1/20 0.45
ALOX15 P16050 1/20 0.45
MAPK1 P28482 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
VCP P55072 1/20 0.44
HSP90AA1 P07900 1/20 0.44
NTSR1 P30989 1/20 0.44
SRC P12931 1/20 0.43
NPC1 O15118 5/20 0.42
LMNA P02545 2/20 0.42
POLB P06746 1/20 0.42
RAB9A P51151 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5143659 0.82 HSP90AA1 (0.57) TSHRKMT2ACES1SMN1; SMN2MEN1
SCHEMBL8627919 0.82 TDP1 (0.53) KMT2ACES1SMN1; SMN2MEN1MAPT
SCHEMBL10428831 0.82 CA1 (0.53) MAPTHPGDCYP3A4NPC1LMNA
SCHEMBL8628903 0.81 HPGD (0.46) TSHRCES1MAPTHPGDKDM4E
SCHEMBL8626139 0.81 APP (0.55) CES1SMN1; SMN2MAPTCYP3A4ALOX15
SCHEMBL10428885 0.81 APP (0.47) TSHRKMT2ACES1SMN1; SMN2MEN1
SCHEMBL8626440 0.80 HDAC8 (0.50) KMT2ASMN1; SMN2MEN1NPC1POLB
SCHEMBL28373176 0.79 TSHR (0.44) TSHRKMT2ACES1SMN1; SMN2MEN1
SCHEMBL8630144 0.79 ERCC5 (0.47) KMT2ASMN1; SMN2MEN1HPGDNPC1
SCHEMBL8628090 0.79 CES2 (0.59) TSHRKMT2ACES1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100048604-A1 Ligands for Aldoketoreductases TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2010-02-25 US disclosed
WO-2006023821-A2 LIGANDS FOR ALDOKETOREDUCTASES THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2006-03-02 WO disclosed
EP-0646570-B1 PROCESS FOR PRODUCING LIGNAN COMPOUND SHIONOGI & CO (JP) 1998-06-24 EP disclosed
US-5488134-A Preparation of compounds of lignan series SHIONOGI & CO., LTD. (JP) 1996-01-30 US disclosed
CN-1109685-A Process for producing lignan compound SHIONOGI & CO (JP) 1995-10-04 CN disclosed
EP-0646570-A1 PROCESS FOR PRODUCING LIGNAN COMPOUND SHIONOGI & CO., LTD. (JP) 1995-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048604-A1 Ligands for Aldoketoreductases AKR1C2, AKR1C1, AKR1B1 TSHR 3650/4885KMT2A 3808/4885CES1 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.